胰高血糖素样肽-1受体激动剂联合钠-葡萄糖共转运蛋白-2抑制剂对心血管及严重肾脏事件发生率的影响:基于人群的队列研究
该基于人群的队列研究采用流行新使用者设计模拟试验,纳入2013年1月至2020年12月间6696例起始GLP-1受体激动剂后加用SGLT-2抑制剂的患者和8942例起始SGLT-2抑制剂后加用GLP-1受体激动剂的患者,按1:1匹配。与单用GLP-1受体激动剂相比,联合治疗与主要不良心血管事件风险降低30%(HR 0.70,95%CI 0.49-0.99)和严重肾脏事件风险降低57%(HR 0.43,95%CI 0.23-0.80)相关。与单用SGLT-2抑制剂相比,联合治疗与主要不良心血管事件风险降低29%(HR 0.71,95%CI 0.52-0.98)相关,严重肾脏事件置信区间宽(HR 0.67,95%CI 0.32-1.41)。
要点
- 与单用GLP-1受体激动剂相比,联合SGLT-2抑制剂与主要不良心血管事件风险降低30%(HR 0.70,95%CI 0.49-0.99)相关。
- 与单用GLP-1受体激动剂相比,联合SGLT-2抑制剂与严重肾脏事件风险降低57%(HR 0.43,95%CI 0.23-0.80)相关。
- 与单用SGLT-2抑制剂相比,联合GLP-1受体激动剂与主要不良心血管事件风险降低29%(HR 0.71,95%CI 0.52-0.98)相关。
- 与单用SGLT-2抑制剂相比,联合GLP-1受体激动剂对严重肾脏事件的风险比HR 0.67(95%CI 0.32-1.41),置信区间宽。
- 次要结局(心肌梗死、缺血性卒中、心血管死亡、心力衰竭、全因死亡)结果相似但置信区间更宽。
适用人群与场景
- 2型糖尿病患者,2013年1月至2020年12月间起始GLP-1受体激动剂后加用SGLT-2抑制剂者(6696例)或起始SGLT-2抑制剂后加用GLP-1受体激动剂者(8942例)。
- 数据来源为英国临床实践研究数据链(Clinical Practice Research Datalink)链接医院统计入院患者护理和英国国家统计局数据库。
研究设计与关键结果
- 研究设计:基于人群的队列研究,采用流行新使用者设计模拟试验;两个队列分别于2013年1月至2020年12月组建,随访至2021年3月底。
- 第一队列6696例起始GLP-1受体激动剂后加用SGLT-2抑制剂;第二队列8942例起始SGLT-2抑制剂后加用GLP-1受体激动剂;联合使用者按1:1与相同背景药物、背景药物使用时长及时间条件倾向评分匹配的患者配对。
- 与单用GLP-1受体激动剂相比,联合SGLT-2抑制剂的主要不良心血管事件发生率为7.0 vs 10.3事件/1000人年,HR 0.70(95%CI 0.49-0.99),风险降低30%。
- 与单用GLP-1受体激动剂相比,联合SGLT-2抑制剂的严重肾脏事件发生率为2.0 vs 4.6事件/1000人年,HR 0.43(95%CI 0.23-0.80),风险降低57%。
- 与单用SGLT-2抑制剂相比,联合GLP-1受体激动剂的主要不良心血管事件发生率为7.6 vs 10.7事件/1000人年,HR 0.71(95%CI 0.52-0.98),风险降低29%。
- 与单用SGLT-2抑制剂相比,联合GLP-1受体激动剂的严重肾脏事件发生率为1.4 vs 2.0事件/1000人年,HR 0.67(95%CI 0.32-1.41),置信区间宽。
- 次要结局(主要不良心血管事件各组分、心力衰竭、全因死亡)结果相似但置信区间更宽。
证据类型、等级与局限
- 证据类型:基于人群的队列研究(流行新使用者设计,模拟试验)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论:在此队列研究中,GLP-1受体激动剂联合SGLT-2抑制剂与单用任一类药物相比,主要不良心血管事件和严重肾脏事件风险更低。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To determine whether the combined use of glucagon-like peptide-1 (GLP-1) receptor agonists and sodium-glucose cotransporter-2 (SGLT-2) inhibitors is associated with a decreased risk of major adverse cardiovascular events and serious renal events compared with either drug class alone among patients with type 2 diabetes, and to assess the effect of the combination on the individual components of major adverse cardiovascular events, heart failure, and all cause mortality.
DESIGN: Population based cohort study using a prevalent new-user design, emulating a trial.
SETTING: UK Clinical Practice Research Datalink linked to Hospital Episode Statistics Admitted Patient Care and Office for National Statistics databases.
PARTICIPANTS: Two prevalent new-user cohorts were assembled between January 2013 and December 2020, with follow-up until the end of March 2021. The first cohort included 6696 patients who started GLP-1 receptor agonists and added on SGLT-2 inhibitors, and the second included 8942 patients who started SGLT-2 inhibitors and added on GLP-1 receptor agonists. Combination users were matched, in a 1:1 ratio, to patients prescribed the same background drug, duration of background drug, and time conditional propensity score.
MAIN OUTCOME MEASURES: Cox proportional hazards models were fitted to estimate the hazard ratios and 95% confidence intervals of major adverse cardiovascular events and serious renal events, separately, comparing the GLP-1 receptor agonist-SGLT-2 inhibitor combination with the background drug, either GLP-1 receptor agonists or SGLT-2 inhibitors, depending on the cohort. Secondary outcomes included associations with the individual components of major adverse cardiovascular events (myocardial infarction, ischaemic stroke, cardiovascular mortality), heart failure, and all cause mortality.
RESULTS: Compared with GLP-1 receptor agonists, the SGLT-2 inhibitor-GLP-1 receptor agonist combination was associated with a 30% lower risk of major adverse cardiovascular events (7.0 v 10.3 events per 1000 person years; hazard ratio 0.70, 95% confidence interval 0.49 to 0.99) and a 57% lower risk of serious renal events (2.0 v 4.6 events per 1000 person years; hazard ratio 0.43, 0.23 to 0.80). Compared with SGLT-2 inhibitors, the GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a 29% lower risk of major adverse cardiovascular events (7.6 v 10.7 events per 1000 person years; hazard ratio 0.71, 0.52 to 0.98), whereas serious renal events generated a wide confidence interval (1.4 v 2.0 events per 1000 person years; hazard ratio 0.67, 0.32 to 1.41). Secondary outcomes generated similar results but with wider confidence intervals.
CONCLUSIONS: In this cohort study, the GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a lower risk of major adverse cardiovascular events and serious renal events compared with either drug class alone.
参考来源
- Simms-Williams N, Treves N, Yin H, et al. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study. BMJ. 2024. PMID: 38663919. doi:10.1136/bmj-2023-078242
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。